Michael Gierend, DVM, Ph.D.
A Founding Partner of PSNResearch, Michael has served in many leadership capacities since our inception in 1997.
See Michael's Expertise
Rafael Zurita, MSc
Rafael is our Chief Executive Officer, and is responsible for driving the company's growth as an agile and adaptive clinical development firm.
Read More About Rafael
Ignazio Di Giovanna, Ph.D.
Ignazio is PSNResearch's Head of Quality Assurance and expert in First-In-Man trials.
See Ignazio's Accomplishments
Antonio Berlanga Ruiz
Antonio chairs the Finance and Operations committees at PSNResearch, and has served since 2010 as a Director on the Board.
Learn More about Antonio
Alejandra Mørk, Ph.D.
Alejandra leads our Drug Development Consulting team, with additional specialities in Clinical Trial Supply.
Read About Alejandra
Paul Bishop
Paul leads all business development efforts at PSNResearch.

Learn More About Paul
Yves Alamercery
Yves is our resident expert in Coronary Artery Disease clinical trials, with 23 years of experience and nearly a dozen scientific publications to his credit.
Learn More About Yves
Odette Jochems, M.D.
Odette brings 36 years of experience with the Dutch healthcare system and its regulatory bodies.

Read About Odette
Lyle Camblos
Lyle leads PSNResearch's Finance and Operations teams, and brings his experience in business operations to the unique challenges of international project management.
Learn More About Lyle

IctalCare launches CE-marked M1 Epilepsy Alarm

IctalCare's success story results from our contribution to their clinical development process: protocol writing, monitoring, data management, statistics, and reporting
Learn more

Arzerra EMA/FDA approved following successful pivotal Phase III trial

Planning, conduct and reporting of a pivotal, phase 3 clinical trial in chronic lymphocytic leukemia (CLL) - 225 patients, 13 countries - resulted in full approval.
Speak With This Partner

Chelsea Therapeutics' Northera (droxidopa) FDA-approved

Following our resuscitation of the pivotal Phase III trial, Northera has received FDA approval.
Read About This Client

Paedriatric Investigational Plan complete and approved for METFIZZ

Our regulatory/medical affairs team has been awarded a EU’s Seventh Framework Programme for Research (FP7) grant for the Phase III study.
Read More